• Molecular NameCinalukast
  • SynonymNA
  • Weight412.554
  • Drugbank_IDDB00587
  • ACS_NO8312-51-6
  • Show 3D model
  • LogP (experiment)5.168
  • LogP (predicted, AB/LogP v2.0)3.88
  • pkaN/A
  • LogD (pH=7, predicted)1.49
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.15
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds9
  • TPSA107.53
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyUsed in the treatment of asthma, cinalukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Cinalukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A